References from Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
No reference evidence is available for this admitted work.
References for Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial | ResearchHub - ResearchHub
